Dr. Karen Reckamp of City of Hope Cancer Center reviews the concept of acquired resistance to targeted therapies in patients with a driver mutation and why it occurs.

One of the major questions in the field of EGFR mutation-positive advanced NSCLC is whether we should continue patients on EGFR tyrosine kinase inhibitor (TKI) therapy as we transition to new treatment options because of acquired resistance after an initial good response.